ES2323634T5 - Proteínas quiméricas l1 del virus del papiloma humano 16 que contienen un péptido l2, partículas tipo virus preparadas a partir de estas proteínas y un método para preparar las partículas - Google Patents
Proteínas quiméricas l1 del virus del papiloma humano 16 que contienen un péptido l2, partículas tipo virus preparadas a partir de estas proteínas y un método para preparar las partículas Download PDFInfo
- Publication number
- ES2323634T5 ES2323634T5 ES03727750T ES03727750T ES2323634T5 ES 2323634 T5 ES2323634 T5 ES 2323634T5 ES 03727750 T ES03727750 T ES 03727750T ES 03727750 T ES03727750 T ES 03727750T ES 2323634 T5 ES2323634 T5 ES 2323634T5
- Authority
- ES
- Spain
- Prior art keywords
- hpv
- dna sequence
- polypeptide
- peptide
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000002245 particle Substances 0.000 title claims description 13
- 241000341655 Human papillomavirus type 16 Species 0.000 title claims description 7
- 108090000623 proteins and genes Proteins 0.000 title description 16
- 102000004169 proteins and genes Human genes 0.000 title description 10
- 108020001507 fusion proteins Proteins 0.000 title description 4
- 102000037865 fusion proteins Human genes 0.000 title description 4
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 60
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 38
- 229920001184 polypeptide Polymers 0.000 claims abstract description 35
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims abstract description 9
- 239000013598 vector Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 2
- 230000009851 immunogenic response Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000009465 prokaryotic expression Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 241001631646 Papillomaviridae Species 0.000 description 7
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 2
- 241000531104 Kappapapillomavirus 1 Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710132701 Protein L1 Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940032313 prophylactic HPV vaccine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200203957 | 2002-05-17 | ||
| ZA200203957 | 2002-05-17 | ||
| ZA02/3957 | 2002-05-17 | ||
| PCT/IB2003/001912 WO2003097673A2 (en) | 2002-05-17 | 2003-05-19 | Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2323634T3 ES2323634T3 (es) | 2009-07-22 |
| ES2323634T5 true ES2323634T5 (es) | 2012-09-04 |
Family
ID=29550639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03727750T Expired - Lifetime ES2323634T5 (es) | 2002-05-17 | 2003-05-19 | Proteínas quiméricas l1 del virus del papiloma humano 16 que contienen un péptido l2, partículas tipo virus preparadas a partir de estas proteínas y un método para preparar las partículas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7407807B2 (enExample) |
| EP (1) | EP1506222B2 (enExample) |
| JP (2) | JP4614765B2 (enExample) |
| AT (1) | ATE424409T1 (enExample) |
| AU (1) | AU2003232951B2 (enExample) |
| CA (1) | CA2486450C (enExample) |
| CY (1) | CY1109257T1 (enExample) |
| DE (1) | DE60326449D1 (enExample) |
| DK (1) | DK1506222T3 (enExample) |
| ES (1) | ES2323634T5 (enExample) |
| PT (1) | PT1506222E (enExample) |
| SI (1) | SI1506222T1 (enExample) |
| WO (1) | WO2003097673A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0228715D0 (en) * | 2002-12-09 | 2003-01-15 | Glaxosmithkline Biolog Sa | Vaccine |
| CN101166827B (zh) | 2005-04-29 | 2013-09-04 | 开普敦大学 | 在植物中表达蛋白质 |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| CN1328287C (zh) * | 2005-12-29 | 2007-07-25 | 西安交通大学 | Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途 |
| US20100260792A1 (en) * | 2007-10-22 | 2010-10-14 | University Of Rochester | Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres |
| CA2768172A1 (en) * | 2009-06-25 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Novel compositions |
| WO2011017162A2 (en) * | 2009-08-03 | 2011-02-10 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
| CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
| CN103890177B (zh) * | 2011-12-01 | 2016-03-09 | 开普敦大学 | Hpv嵌合颗粒 |
| WO2015009853A1 (en) * | 2013-07-16 | 2015-01-22 | University Of Louisville Research Foundation, Inc. | Compositions for mucusal delivery, useful for treating papillomavirus infections |
| WO2015192018A1 (en) | 2014-06-12 | 2015-12-17 | Iowa Approach Inc. | Method and apparatus for rapid and selective tissue ablation with cooling |
| JP7017811B2 (ja) * | 2020-02-13 | 2022-02-09 | 国立研究開発法人農業・食品産業技術総合研究機構 | ウイルス様粒子及びその使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
| EP1728800A1 (de) * | 1994-10-07 | 2006-12-06 | Loyola University Of Chicago | Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung |
| GB9621091D0 (en) * | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| US6228368B1 (en) † | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| DE19812941A1 (de) † | 1998-03-24 | 1999-10-07 | Medigene Ag | Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor |
| US6926897B1 (en) † | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| DE69933875T2 (de) * | 1998-08-14 | 2007-05-31 | Merck & Co., Inc. | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. |
| GB9921146D0 (en) † | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| EP2416798B1 (en) † | 2009-04-10 | 2017-09-20 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
-
2003
- 2003-05-19 US US10/514,878 patent/US7407807B2/en not_active Expired - Fee Related
- 2003-05-19 WO PCT/IB2003/001912 patent/WO2003097673A2/en not_active Ceased
- 2003-05-19 AU AU2003232951A patent/AU2003232951B2/en not_active Ceased
- 2003-05-19 AT AT03727750T patent/ATE424409T1/de active
- 2003-05-19 CA CA2486450A patent/CA2486450C/en not_active Expired - Fee Related
- 2003-05-19 DE DE60326449T patent/DE60326449D1/de not_active Expired - Lifetime
- 2003-05-19 SI SI200331600T patent/SI1506222T1/sl unknown
- 2003-05-19 JP JP2004506346A patent/JP4614765B2/ja not_active Expired - Fee Related
- 2003-05-19 ES ES03727750T patent/ES2323634T5/es not_active Expired - Lifetime
- 2003-05-19 PT PT03727750T patent/PT1506222E/pt unknown
- 2003-05-19 EP EP03727750A patent/EP1506222B2/en not_active Expired - Lifetime
- 2003-05-19 DK DK03727750T patent/DK1506222T3/da active
-
2008
- 2008-07-16 US US12/174,104 patent/US8163557B2/en not_active Expired - Lifetime
-
2009
- 2009-06-04 CY CY20091100595T patent/CY1109257T1/el unknown
-
2010
- 2010-06-16 JP JP2010137490A patent/JP2010263899A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20060035319A1 (en) | 2006-02-16 |
| US8163557B2 (en) | 2012-04-24 |
| EP1506222B2 (en) | 2012-05-23 |
| CA2486450A1 (en) | 2003-11-27 |
| AU2003232951A1 (en) | 2003-12-02 |
| JP4614765B2 (ja) | 2011-01-19 |
| EP1506222B1 (en) | 2009-03-04 |
| US7407807B2 (en) | 2008-08-05 |
| PT1506222E (pt) | 2009-06-12 |
| ATE424409T1 (de) | 2009-03-15 |
| WO2003097673A2 (en) | 2003-11-27 |
| AU2003232951B2 (en) | 2009-07-23 |
| EP1506222A2 (en) | 2005-02-16 |
| DE60326449D1 (de) | 2009-04-16 |
| WO2003097673B1 (en) | 2004-04-22 |
| WO2003097673A3 (en) | 2004-03-18 |
| CY1109257T1 (el) | 2014-07-02 |
| CA2486450C (en) | 2013-11-19 |
| SI1506222T1 (sl) | 2009-10-31 |
| US20090047302A1 (en) | 2009-02-19 |
| ES2323634T3 (es) | 2009-07-22 |
| DK1506222T3 (da) | 2009-07-06 |
| JP2010263899A (ja) | 2010-11-25 |
| JP2006507797A (ja) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8163557B2 (en) | Chimaeric human papillomavirus 16 L1 virus-like particles and a method for preparing the particles | |
| ES2337492T3 (es) | Formulaciones y formas de uso de la vacuna capsomero de virus de papiloma. | |
| ES2263405T3 (es) | Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. | |
| ES2275965T3 (es) | Papiloma virus recombinante l1. | |
| Suzich et al. | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. | |
| ES2213754T3 (es) | Particulas quimericas de tipo papilomavirus. | |
| ES2340287T3 (es) | Expresion optimizada de hpv 58 l1 en levadura. | |
| ES2301551T3 (es) | Moleculas l1 de papilomavirus humano (hpv) quimericas y usos de las mismas. | |
| ES2317910T3 (es) | Formas (fijas) estables e proteinas de capside l1 virales, proteinas de fusion y sus utilizaciones. | |
| Fligge et al. | Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33 | |
| JP2002516291A (ja) | パピローマウイルス・ウイルス様粒子による経口免疫感作 | |
| US7182947B2 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
| JP4945730B2 (ja) | 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原 | |
| US7494658B2 (en) | Papilloma virus truncated L1 protein and fusion protein constructs | |
| Deng et al. | The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro | |
| WO2006065166A1 (en) | Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection | |
| HK1094340A (en) | Papilloma virus capsomere vaccine formulations and methods of use |